Immunovant (Immunovant) Risk Assessment

View and export this data going back to 2019. Start your Free Trial

What is Immunovant Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Immunovant is: No Data: Cannot be evaluated.

Competitive Comparison of Immunovant's Risk Assessment

For the Biotechnology subindustry, Immunovant's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunovant's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunovant's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Immunovant's Risk Assessment falls into.

Immunovant (NAS:IMVTU) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Immunovant Risk Assessment Related Terms

Thank you for viewing the detailed overview of Immunovant's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunovant (Immunovant) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunovant Inc (NAS:IMVTU) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

IMVT:USA

Address

320 West 37th Street, 6th Floor, New York, NY, USA, 10018

Website

https://www.immunovant.com

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

Executives

Roivant Sciences Ltd.	10 percent owner	CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Julia G. Butchko	officer: Chief Dev. & Tech. Officer	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Michael James Elliott	officer: Chief Scientific Officer	320 WEST 37TH STREET, NEW YORK NY 10018
George V Migausky	director	C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Frank Torti	director	2855 SAND HILL ROAD, MENLO PARK CA 94025
Peter Salzmann	director, officer: Chief Executive Officer	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
W Bradford Middlekauff	officer: General Counsel	200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Douglas J. Hughes	director	C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Atul Pande	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Andrew J. Fromkin	director	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
Pamela Ann Connealy	officer: Chief Financial Officer	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Eric Venker	director	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
Robert K Zeldin	officer: Chief Medical Officer	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Health Sciences Holdings, Llc	10 percent owner	412 WEST 15TH STREET, FLOOR 9, NEW YORK NY 10011